FDA Accepts Resubmitted NDA for Arimoclomol for Niemann-Pick Disease Type C

The FDA has accepted the resubmitted New Drug Application (NDA) for arimoclomol for the treatment of Niemann-Pick disease type C.

Related Keywords

,Drug Administration ,European Union ,New Drug Application ,Complete Response Letter ,Severity Scale ,